CIAM
FATE icon

Caitong International Asset Management’s Fate Therapeutics FATE Stock Holding History

Caitong International Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.3K Buy
29,002
+29,001
+2,900,100% +$53.7K 0.01% 612
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 2473
2025
Q1 		– Sell
-237
Closed -$391 – 2275
2024
Q4 		$391 Buy
+237
New +$597 ﹤0.01% 1497

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Caitong International Asset Management's FATE Position: Q2 2026 in Review

Caitong International Asset Management increased its Fate Therapeutics (FATE) stake by 2,900,100% in Q2 2026, buying an estimated $53.7K and bringing the position to 29,002 shares worth $78.3K. The position accounts for 0.01% of the portfolio, ranked #612.

Caitong International Asset Management first reported a position in FATE in Q4 2024 and has held it in 3 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Caitong International Asset Management held 29,002 shares of Fate Therapeutics worth $78.3K as of Q2 2026.
  • Caitong International Asset Management bought 29,001 Fate Therapeutics shares in Q2 2026, an estimated $53.7K.
  • Fate Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #612 holding.
  • Caitong International Asset Management first reported a position in Fate Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.